Top

Nuclear Medicine and Molecular Imaging

Published in:

01-03-2012 | Original Article

Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study

Authors: Jai Hyuen Lee, Won Ae Lee, Seok Gun Park, Dong Kook Park, Hwan Namgung

Published in: Nuclear Medicine and Molecular Imaging | Issue 1/2012

Abstract

Purpose

The clinical availability of 2-deoxy-2-[18F] fluoro-D-glucose (FDG) dual-time point positron emission tomography/computerized tomography (DTPP) has been investigated in diverse oncologic fields. The aim of this preliminary study was to evaluate the relationship between various immunohistopathologic markers reflecting disease progression of colorectal cancer and parameters extracted from FDG DTPP in colorectal cancer patients.

Materials and Methods

Forty-seven patients with histologically confirmed colorectal cancer were analyzed in this preliminary study. FDG DTPP consisted of an early scan 1 h after FDG injection and a delayed scan 1.5 h after the early scan. Based on an analysis of FDG DTPP, we estimated the maximum standardized uptake value (SUV) of tumors on the early and delayed scans (SUV_early and SUV_delayed, respectively). The retention index (RI) was calculated as follows: (SUV_delayed - SUV_early) × 100/ SUV_early. The clinicopathological findings (size and T and N stages) and immunohistochemical factors [glucose transporter 1 (GLUT-1), hexokinase 2 (HK-2), p53, P504S, and β-catenin] were analyzed by visual analysis.

Results

The RIs calculated from the SUVs ranged from -1.8 to 73.4 (31.8 ± 15.5). The RIs were significantly higher in patients with high T stages (T3 and T4) than with low T stages (T1 and T2; p < 0.05). Among the immunohistochemical analytic markers, GLUT-1 had the highest positive staining rate (93.6%) compared to other markers. Based on univariable analysis, it was shown that the RI of high-level GLUT-1 expression was significantly higher than low-level GLUT-1 expression (p = 0.01), and the RI of high-level p53 expression was slightly higher than low-level p53 expression (p = 0.08). Multivariate analysis to investigate a link between RI and clinicopathologic parameters of colorectal carcinoma showed that GLUT-1, p53, and T staging were independently connected with increased RIs (p < 0.05, total) using backward selection methods. There was no significant statistical relationship between SUV_early and SUV_delayed and clinicopathologic parameters in this study.

Conclusion

The RIs obtained from preoperative colorectal cancers had a significant relationship to tumor size, T staging, GLUT-1, and p53, in contrast to SUV_early or SUV_delayed. Compared with previous reports, our results showed that RI can better predict GLUT-1 expression than HK-2 and other immunohistochemical markers. This study demonstrated that the RI might have the potential to be applied as a prognostic marker in preoperative colorectal cancer.

Sorensen M, Mortensen FV, Hoyer M, Vilstrup H, Keiding S. FDG-PET improves management of patients with colorectal liver metastases allocated for local treatment: a consecutive prospective study. Scand J Surg. 2007;96:209–13.PubMed

Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009;50:1036–41.PubMedCrossRef

Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–32.PubMedCrossRef

Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18 F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.PubMedCrossRef

Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345–8.PubMedCrossRef

Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18 F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–7.PubMed

Houseni M, Chamroonrat W, Zhuang J, Gopal R, Alavi A, Zhuang H. Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med. 2010;51:535–42.PubMedCrossRef

Nishiyama Y, Yamamoto Y, Kimura N, Ishikawa S, Sasakawa Y, Ohkawa M. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer. Ann Nucl Med. 2008;22:245–50.PubMedCrossRef

Uesaka D, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Sasaki M, et al. Evaluation of dual-time-point 18 F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008;49:1606–12.PubMedCrossRef

10.

Kim S, Chung JK, Kim BT, Kim SJ, Jeong JM, Lee DS, et al. Relationship between Gastrointestinal F-18-fluorodeoxyglucose Accumulation and Gastrointestinal Symptoms in Whole-Body PET. Clin Positron Imaging. 1999;2:273–9.PubMedCrossRef

11.

Chung JK, Lee YJ, Kim C, Choi SR, Kim M, Lee K, et al. Mechanisms related to [18 F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med. 1999;40:339–46.PubMed

12.

Lyshchik A, Higashi T, Hara T, Nakamoto Y, Fujimoto K, Doi R, et al. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 2007;25:154–62.PubMedCrossRef

13.

Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, et al. Recent chemotherapy reduces the sensitivity of [18 F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005;23:8713–6.PubMedCrossRef

14.

Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, Larson SM, et al. Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia. 2001;3:189–95.PubMedCrossRef

15.

Nassar A, Amin MB, Sexton DG, Cohen C. Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol. 2005;13:252–5.PubMedCrossRef

16.

Jiang Z, Fanger GR, Banner BF, Woda BA, Algate P, Dresser K, et al. A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev. 2003;27:422–6.PubMedCrossRef

17.

Chen S, Liu J, Li G, Mo F, Xu X, Zhang T, et al. Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis. Scand J Gastroenterol. 2008;43:456–64.PubMedCrossRef

18.

Han SA, Chun H, Park CM, Kang SJ, Kim SH, Sohn D, et al. Prognostic significance of beta-catenin in colorectal cancer with liver metastasis. Clin Oncol (R Coll Radiol). 2006;18:761–7.CrossRef

19.

Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res. 2004;10:1401–8.PubMedCrossRef

20.

Sahlmann CO, Siefker U, Lehmann K, Meller J. Dual time point 2-[18 F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun. 2004;25:819–23.PubMedCrossRef

21.

Sathekge MM, Maes A, Pottel H, Stoltz A, van de Wiele C. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J. 2010;100:598–601.PubMed

22.

Umeda Y, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Saito Y, et al. Dual-time-point 18 F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging. 2009;36:1121–30.PubMedCrossRef

23.

Umeda Y, Demura Y, Morikawa M, Ameshima S, Tsuchida T, Fujibayashi Y, et al. Prognostic value of dual time point (18) F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology. 2011;16:713–20.PubMedCrossRef

24.

Sanghera B, Wong WL, Lodge MA, Hain S, Stott D, Lowe J, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun. 2005;26:861–7.PubMedCrossRef

25.

Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34–40.PubMedCrossRef

26.

Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res. 1996;2:1151–4.PubMed

27.

Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001;37:204–9.PubMedCrossRef

28.

Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol. 2008;97:51–6.PubMedCrossRef

29.

Okubo R, Masuda H, Nemoto N. p53 mutation found to be a significant prognostic indicator in distal colorectal cancer. Oncol Rep. 2001;8:509–14.PubMed

30.

Kaklamanis L, Savage A, Whitehouse R, Doussis-Anagnostopoulou I, Biddolph S, Tsiotos P, et al. Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. Br J Cancer. 1998;77:1864–9.PubMedCrossRef

31.

Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173–80.PubMed

32.

Hamada K, Tomita Y, Qiu Y, Tomoeda M, Ueda T, Tamai N, et al. (18)F-FDG PET analysis of schwannoma: increase of SUV_max in the delayed scan is correlated with elevated VEGF/VPF expression in the tumors. Skeletal Radiol. 2009;38:261–6.PubMedCrossRef

33.

Prante O, Maschauer S, Fremont V, Reinfelder J, Stoehr R, Szkudlinski M, et al. Regulation of uptake of 18 F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med. 2009;50:1364–70.PubMedCrossRef

Title: Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study
Authors: Jai Hyuen Lee
Won Ae Lee
Seok Gun Park
Dong Kook Park
Hwan Namgung
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Nuclear Medicine and Molecular Imaging / Issue 1/2012
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-011-0120-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study

Abstract

Purpose

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Retrocrural Lymph Node Metastasis Disclosed by 18F-FDG PET/CT: A Predictor of Supra-diaphragmatic Spread in Ovarian Cancer

Compression of the Right Pulmonary Artery by a Massive Descending Aortic Aneurysm Causing Bilateral Perfusion Defects on Pulmonary Scintigraphy

Prosthesis-Related Abscess on In-111 Leukocyte SPECT/CT Imaging

The Feasibility of 18F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer

Optical Imaging for Stem Cell Differentiation to Neuronal Lineage

Monitoring Therapeutic Response in a Case of Extrapulmonary Tuberculosis by Serial F-18 FDG PET/CT